Compelo Packaging is using cookies

ContinueLearn More
Close
Dismiss

Clariant adds distribution of Bormed resins to portfolio

Chemicals firm Clariant has added distribution of Bormed resins to portfolio and the company is offering future-proofing for next-gen drug packaging, delivery devices at MD&M 2018.

Planned to take place from 6-8 February, the event will be held ahead of the new United States Pharmacopeia (USP) regulations.

The company has already completed USP-compliance testing for pigment and additive ingredients in its Mevopur and Remafin-EP product ranges for pharmaceutical packaging applications.

Following the completion of the tests, the company has opened new options for manufacturers who intend to change their drug packaging.

Clariant Medical and Pharmaceutical North America segment manager Eric Rohr said: "The availability of compliant and change-controlled ingredients today means we can help pharmaceutical customers get out in front of these regulatory changes and avoid the potential for last-minute problems with testing as the 2020 deadline approaches."

Meanwhile, Clariant said it has also been selected as a distributor of Austria-based firm Borealis’ Bormed solutions of dedicated healthcare polyolefins.

As part of the agreement, Clariant will be responsible for the selling the complete Bormed portfolio of homopolymer and random copolymer polypropylene (PP) as well as high-density polyethylene (HDPE) and Low-density polyethylene (LDPE) resins.

The company can also provide Bormed resins as 'ready to use' Mevopurcompounds.

Bormed solutions are used for a wide range of medical devices, diagnostics and pharmaceutical packaging, including syringes, inhalers, intravenous (IV) bags dialysis filters, pipette tips, and packaging such as bottles and blow-fill seal (BFS) vials.

Rohr added: “The Bormed service package based on Borealis' commitment, service and compliance to the healthcare industry complements Clariant's Mevopur promise for medical devices and packaging.

“They are change-controlled, produced to consistently high standards, and tested for assured compliance with relevant European and US Pharmacopeia and ISO standards.”


Image: Clariant completed USP-compliance testing for pigment and additive ingredients in its Mevopur and Remafin-EP product ranges. Photo: courtesy of Clariant.